Loading clinical trials...
Loading clinical trials...
A Phase 2 Clinical Trial of Nalirifox as Neoadjuvant Treatment for Patients With Borderline Resectable Pancreatic Ductal Adenocarcinoma (Nectar Study)
Conditions
Interventions
Biospecimen Collection
Computed Tomography
+5 more
Locations
1
United States
Roswell Park Cancer Institute
Buffalo, New York, United States
Start Date
March 2, 2026
Primary Completion Date
March 1, 2027
Completion Date
March 1, 2027
Last Updated
April 1, 2026
Lead Sponsor
Roswell Park Cancer Institute
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions